[go: up one dir, main page]

AR035411A1 - USE OF A TACROLIMUS DERIVATIVE TO MANUFACTURE A NEUROTROPHIC AGENT, COMPOSITIONS AND MANUFACTURING ITEMS OR KITS THAT UNDERSTAND IT, METHOD FOR MANUFACTURING AN AGENT THAT UNDERSTANDS AND FABRICS AND GRAINTS WITH A NERVOUS CELL TREATED WITH THIS COMPOSITE - Google Patents

USE OF A TACROLIMUS DERIVATIVE TO MANUFACTURE A NEUROTROPHIC AGENT, COMPOSITIONS AND MANUFACTURING ITEMS OR KITS THAT UNDERSTAND IT, METHOD FOR MANUFACTURING AN AGENT THAT UNDERSTANDS AND FABRICS AND GRAINTS WITH A NERVOUS CELL TREATED WITH THIS COMPOSITE

Info

Publication number
AR035411A1
AR035411A1 ARP010106058A ARP010106058A AR035411A1 AR 035411 A1 AR035411 A1 AR 035411A1 AR P010106058 A ARP010106058 A AR P010106058A AR P010106058 A ARP010106058 A AR P010106058A AR 035411 A1 AR035411 A1 AR 035411A1
Authority
AR
Argentina
Prior art keywords
agent
manufacturing
manufacture
derivative
graints
Prior art date
Application number
ARP010106058A
Other languages
Spanish (es)
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of AR035411A1 publication Critical patent/AR035411A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

El uso de un derivado de tacrolimus de fórmula (1) para la fabricación de un agente neurotrófico. El derivado de fórmula (1) posee un nivel alto de actividad neurotrófica y un nivel reducido de actividad inmunosupresora. Composición que comprende al derivado de fórmula (1) y un artículo de fabricación o un kit que comprende un material de envasado dentro del que se incluye el compuesto (1). Métodos para realizar o fabricar un agente neurotrófico que comprende al compuesto (1). Composición que comprende una célula nerviosa tratada con el compuesto (1). Tejido o injerto que comprenden una célula nerviosa tratada con el compuesto de fórmula (1). Composición que comprende una célula, tejido o injerto tratados con el compuesto (1) y al menos un agente promotor del crecimiento de la célula nerviosa.The use of a tacrolimus derivative of formula (1) for the manufacture of a neurotrophic agent. The derivative of formula (1) has a high level of neurotrophic activity and a reduced level of immunosuppressive activity. Composition comprising the derivative of formula (1) and an article of manufacture or a kit comprising a packaging material within which the compound (1) is included. Methods for making or manufacturing a neurotrophic agent comprising the compound (1). Composition comprising a nerve cell treated with the compound (1). Tissue or graft comprising a nerve cell treated with the compound of formula (1). Composition comprising a cell, tissue or graft treated with the compound (1) and at least one nerve cell growth promoting agent.

ARP010106058A 2000-12-29 2001-12-27 USE OF A TACROLIMUS DERIVATIVE TO MANUFACTURE A NEUROTROPHIC AGENT, COMPOSITIONS AND MANUFACTURING ITEMS OR KITS THAT UNDERSTAND IT, METHOD FOR MANUFACTURING AN AGENT THAT UNDERSTANDS AND FABRICS AND GRAINTS WITH A NERVOUS CELL TREATED WITH THIS COMPOSITE AR035411A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25850000P 2000-12-29 2000-12-29

Publications (1)

Publication Number Publication Date
AR035411A1 true AR035411A1 (en) 2004-05-26

Family

ID=22980816

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010106058A AR035411A1 (en) 2000-12-29 2001-12-27 USE OF A TACROLIMUS DERIVATIVE TO MANUFACTURE A NEUROTROPHIC AGENT, COMPOSITIONS AND MANUFACTURING ITEMS OR KITS THAT UNDERSTAND IT, METHOD FOR MANUFACTURING AN AGENT THAT UNDERSTANDS AND FABRICS AND GRAINTS WITH A NERVOUS CELL TREATED WITH THIS COMPOSITE

Country Status (18)

Country Link
EP (1) EP1353671A4 (en)
JP (1) JP2004527472A (en)
KR (2) KR20070030331A (en)
CN (1) CN1293877C (en)
AR (1) AR035411A1 (en)
AU (1) AU2002231277B2 (en)
BR (1) BR0116762A (en)
CA (1) CA2433384A1 (en)
CZ (1) CZ20032060A3 (en)
HU (1) HUP0302521A3 (en)
IL (1) IL156664A0 (en)
MX (1) MXPA03005941A (en)
NO (1) NO20032913D0 (en)
NZ (1) NZ527209A (en)
PL (1) PL366301A1 (en)
RU (1) RU2288716C2 (en)
WO (1) WO2002053159A1 (en)
ZA (1) ZA200305806B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
EP1706117A1 (en) * 2004-01-20 2006-10-04 Astellas Pharma Inc. Method for treating erectile dysfunction
EP1810675A1 (en) * 2006-01-18 2007-07-25 Institut Curie Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421
JP2009102226A (en) * 2006-02-14 2009-05-14 Meiji Milk Prod Co Ltd Spinal cord injury treatment
BRPI0916232A2 (en) * 2008-07-23 2017-08-29 Novartis Ag SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS AND THEIR USE TO TREAT MUSCLE INFLAMMATION
EP2817009A1 (en) * 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US537663A (en) * 1895-04-16 wubstee
ES2071681T3 (en) * 1987-12-09 1995-07-01 Fisons Plc MACROCYCLE COMPOUNDS.
GR1001225B (en) * 1989-09-14 1993-06-30 Fisons Plc Novel macrocyclic compositions and new application method thereof
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5541193A (en) * 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
GB9202196D0 (en) * 1992-02-01 1992-03-18 Fisons Plc Method of treatment
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use

Also Published As

Publication number Publication date
KR100794204B1 (en) 2008-01-14
NO20032913D0 (en) 2003-06-24
IL156664A0 (en) 2004-01-04
CZ20032060A3 (en) 2004-01-14
BR0116762A (en) 2004-08-10
NZ527209A (en) 2005-09-30
RU2288716C2 (en) 2006-12-10
RU2003123493A (en) 2005-01-20
CA2433384A1 (en) 2002-07-11
EP1353671A4 (en) 2004-07-14
AU2002231277B2 (en) 2006-11-30
HUP0302521A2 (en) 2003-11-28
CN1293877C (en) 2007-01-10
WO2002053159A1 (en) 2002-07-11
ZA200305806B (en) 2005-01-26
HUP0302521A3 (en) 2007-03-28
EP1353671A1 (en) 2003-10-22
JP2004527472A (en) 2004-09-09
MXPA03005941A (en) 2005-02-14
PL366301A1 (en) 2005-01-24
CN1538843A (en) 2004-10-20
KR20040007431A (en) 2004-01-24
KR20070030331A (en) 2007-03-15

Similar Documents

Publication Publication Date Title
CO5700767A2 (en) TRANSPLANT REJECTION TREATMENT PROCEDURE
DE60112897D1 (en) STABILIZATION OF IMPLANTABLE BIOPROTHESEE WEAVE
PA8468401A1 (en) COMPOUNDS FOR THE TREATMENT OF ISCHEMIA
ES2104971T3 (en) AMINO-SUBSTITUTED BENZOYLGUANIDINES WITH ANTIARRHYTHMIC PROPERTIES.
AR031975A1 (en) ANALOG COMPOUNDS OF (1R, CIS) -4- (6-AMINO-9H-PURIN-9-IL) -2-CYCLOPENTENE-1-METHANOL, PROCESS FOR PREPARATION, USE IN THE TREATMENT OF VIRAL INFECTIONS, AND PACKING THAT CONTAINS THEM
BR0116345A (en) Smelly Counteracting Compositions
MX2007003093A (en) Laundry treatment compositions.
ECSP045239A (en) ZIPRASIDONE COMPOSITION AND SYNTHETIC CONTROLS
EP1100870A4 (en) Improvement of cardiac function by mesenchymal stem cell transplantation
ES2134937T3 (en) ALKYL-GLUCOSIDE AND ITS USE.
AR035411A1 (en) USE OF A TACROLIMUS DERIVATIVE TO MANUFACTURE A NEUROTROPHIC AGENT, COMPOSITIONS AND MANUFACTURING ITEMS OR KITS THAT UNDERSTAND IT, METHOD FOR MANUFACTURING AN AGENT THAT UNDERSTANDS AND FABRICS AND GRAINTS WITH A NERVOUS CELL TREATED WITH THIS COMPOSITE
MX9800680A (en) Synergistic fungicidal composition including a strobilurine analogue compound.
UY28622A1 (en) QUINOLONA ANTIBACTERIAL AGENTS
TR200101583T2 (en) Wood preservative formulations.
AR022017A1 (en) AN AGENT TO TREAT THE DISORDER OF THE FUNCTION OF VISUAL CELLS. THE METHOD OF TREATMENT AND THE USE OF SUCH AGENT FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION
ES2189206T3 (en) BETA-ALCOXIACRYLATES AGAINST MALARIA.
CA2433596A1 (en) Compositions for pre-treating shoes and methods and articles employing same
FI913933A0 (en) GENOMGAOENDE TAECK- OCH TAETNINGSMEDEL BASERADE PAO POLYURETANDISPERSIONER.
CO5040014A1 (en) FUNGICIDE BLENDS
ES2054933T3 (en) CYCLOPROPANOCARBOXAMIDS, PROCEDURE FOR THEIR OBTAINING AND USE FOR THE FIGHT AGAINST PESTS.
ES2126304T3 (en) SUPPORT FOR THE CULTIVATION OF THE MUSHROOMS, WHICH FAVORS THE GROWTH OF THE MYCELIUM AND THE DEVELOPMENT OF THE CARPOPHORES, AS WELL AS THEIR PROCEDURE FOR OBTAINING.
AR034363A1 (en) COMPOSITIONS AND METHOD OF MANUFACTURING OF IMPROVED PULP.
AU2003210127A1 (en) Fireproofing agent
BR0017184A (en) Acyclic monoterpenes as anti-germinating agents for potato tubers
BRPI0509784A (en) fungicidal mixtures to combat phytopathogenic harmful fungi, agent, process to combat phytopathogenic harmful fungi, seed, and use of compounds

Legal Events

Date Code Title Description
FB Suspension of granting procedure